Home > Press > NN-Labs Receives $2 million in SBIR Contracts
NN-Labs Receives $2 million in SBIR Contracts
Fayetteville, AR | Posted on October 17, 2006
NN-Labs, LLC (Nanomaterials and Nanofabrication Laboratories), an Arkansas based nanotechnology firm, was recently awarded three Small Business Innovation Research (SBIR) contracts. The awards consist of two Phase II contracts, from the National Institutes of Health (NIH) and the National Science Foundation (NSF), and one Phase I contract from NIH; all three contracts total $1.8 million. Work on these new projects is already underway.
The funds will aid in NN-Labs’ ability to extend its strength in nanocrystals into end products in the biomedical field. Currently, cadmium containing semiconductor nanocrystals constitute all of the company’s standardized product lines for semiconductor nanocrystals, also known as quantum dots. While non-cadmium containing nanomaterials, such as gold nanoparticles and iron oxide (Fe3O4) magnetic Nanoparticles, are available through custom orders, the product lines are not yet complete or standardized.
The NIH Phase II, entitled Kits for Converting Nanocrystals to Standard Bio-Medical Reagents, Second Generation Nanocrystal Bio-Medical Labels follows the success of the Phase I that focused on the development of bio-medical labels based on the first generation of semiconductor nanocrystals, CdSe quantum dots. NN-Labs will develop the second generation of quantum dots, which are doped zinc containing semiconductor nanocrystals (d-dots). D-dots will ultimately remove heavy metal cadmium from the current workhorse—cadmium selenide related nanocrystals—of quantum dots. In addition, d-dots are also more durable and have better optical properties when high density emitters are needed. It is expected that these new fluorescence labels will make early diagnosis of various diseases and pathogens more practical and less expensive.
Commercial Scale Production of High Quality and Affordable Fe3O4 Nanocrystals for Nano-Biomedicine is the title of the NSF Phase II contract that will expand upon the product line developed in the Phase I contract. The biomedical applications for these Fe3O4 magnetic nanocrystals cover many aspects of the biomedical field, ranging from diagnostics, detection, therapy, separation, and pollution control, etc, which is at least a multi-billion-dollar market. Yet another variety of nanocrystal is to be developed with funding from the NIH Phase I contract, entitled High Yield and Inexpensive Production of High Quality Gold Nanocrystals as Bio-Labels. Similar to the other contracts, the end goal is to enhance already existing biomedical techniques as well as open the door to novel applications in the biomedical field. NN-Labs strives to complete this Phase I as successfully as we have for other Phase I awards, which will help us to secure the corresponding Phase II award from NIH with additional funding of $750K for two years.
NN-Labs has been business active for about four years, since July of 2002. The company has received 15 SBIR contracts (about $5m in total) that have partially funded the development of four standardized product lines, with several other product lines that are still under development and in the trial sales stage. The company maintains affiliations with the University of Arkansas and the Arkansas Science and Technology Authority (ASTA). NN-Labs is also a member of the Genesis Technology Incubator. Additional information about NN-Labs can be found on the company’s website, www.nn-labs.com, or by contacting Leah Sheridan at 479-575-2723 or firstname.lastname@example.org.
Copyright © NN-Labs, LLC
If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Harris & Harris Group Notes ABSMaterials' Series B Financing November 22nd, 2013
Harris & Harris Group Letter to Shareholders on Website November 18th, 2013
Harris & Harris Group Reports Financial Statements as of September 30, 2013 November 12th, 2013
Harris & Harris Group Notes CordenPharma's Acquisition of Ancora's Carbohydrate Synthesis Platform and Corporate Name November 7th, 2013
Nanobiotix strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar: 1 product, 2 skills December 6th, 2013
The gene sequencing that everyone can afford in future December 6th, 2013
Dissolving electronics, energy: Kavli lectures at American Chemical Society meeting December 5th, 2013
Laser light at useful wavelengths from semiconductor nanowires: Nanowire lasers could work with silicon chips, optical fibers, even living cells December 5th, 2013
Nano Labs Anti-Corrosion Paint Utilized in Rehabilitation of Convention Center December 6th, 2013
Coal yields plenty of graphene quantum dots: Rice U. scientists find simple method for producing dots in bulk from coal, coke December 6th, 2013
Stepping-up the Performance of Structural Ceramics: Innovnano produces nanostructured 3YSZ powder for demanding applications December 5th, 2013
Books with New Concepts/Technology for Pulp, Paper and Allied Industries: Author- Dr. Mahendra Patel, Publisher- Industrypaper December 5th, 2013
Leti Presentation at IEDM 2013 Will Report Phase-Change Memory Developments for Microcontroller Embedded Applications December 7th, 2013
Leti Announces Update of UTSOI Model that Allows Designers To Improve Trade-Off between Performance and Power Use December 7th, 2013
Steve Janack to Join Behan Communications and Lead Firm’s New Innovation Practice Group December 7th, 2013
Optical Quality Improvement of Electrical Circuits’ Electrode Zinc Oxide Nanowires December 7th, 2013